Analysts expect Neuphoria Therapeutics Inc. to report revenue of 0.00 for 2027, against a range of 0.00 to 0.00. The most recent reported year, 2026, came in at 0.00.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 183,700.00 | 943,160.00 | 958,610.00 | 15.65 M | 0.00 | - | - | ||
| High Estimate | -676,756.47 | 815,508.45 | 1.78 M | 11.57 M | 0.00 | 0.00 | 0.00 | ||
| Low Estimate | -735,463.89 | 694,133.25 | 1.57 M | 10.58 M | 0.00 | 0.00 | 0.00 | ||
| Consensus Estimate | -706,110.18 | 754,820.85 | 1.68 M | 11.08 M | 0.00 | 0.00 | 0.00 |
Analysts expect Neuphoria Therapeutics Inc. to report earnings per share of -2.54 for 2027, against a range of -2.79 to -2.29. The most recent reported year, 2026, came in at -4.07, a 3.0% miss against the -3.95 consensus.
| Metric | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -30.10 | -29.64 | -21.62 | -0.23 | -4.07 | - | - | ||
| High Estimate | -28.98 | -25.28 | -26.66 | 0.44 | -3.80 | -2.29 | -2.49 | ||
| Low Estimate | -32.26 | -29.80 | -32.36 | 0.36 | -4.10 | -2.79 | -2.69 | ||
| Consensus Estimate | -30.62 | -27.54 | -29.51 | 0.40 | -3.95 | -2.54 | -2.59 |
Pull Wall Street consensus for Neuphoria Therapeutics Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=NEUP&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "NEUP", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=NEUP&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();